Skip to main content

Table 1 The chi-square test of the relationship between risk score and clinical features in TCGA cohort

From: Eight-gene metabolic signature related with tumor-associated macrophages predicting overall survival for hepatocellular carcinoma

Clinical feature Risk Score c2 P
High risk n(%) Low risk n(%)
Age    0.931 0.335
 >65 59 (46.46%) 68 (53.54%)   
  ≤ 65 112 (51.85%) 104 (48.15%)   
BMI    1.275 0.259
 >25 71 (46.41%) 82 (53.59%)   
  ≤ 25 86 (52.76%) 77 (47.24%)   
Family cancer history    0.149 0.7
 NO 29 (23.58%) 94 (76.42%)   
 YES 19 (26.03%) 54 (73.97%)   
Gender    2.032 0.154
 female 61 (55.45%) 49 (44.55%)   
 male 110 (47.21%) 123 (52.79%)   
Tumor status    10.08931 0.001
 tumor free 73 (40.78%) 106 (59.22%)   
 with tumor 87 (58.39%) 62 (41.61%)   
New tumor event    4.85 0.028
 no 71 (43.83%) 91 (56.17%)   
 yes 94 (55.95%) 74 (44.05%)   
Prior Malignancy    2.815 0.093
 no 160 (51.28%) 152 (48.72%)   
 yes 11 (35.48%) 20 (64.52%)   
Histologic Grade    14.724 <0.001
 G1–2 90 (42.06%) 124 (57.94%)   
 G3–4 79 (63.71%) 45 (36.29%)   
Stage    13.911 <0.001
 I-II 104 (43.70%) 134 (56.30%)   
 III-IV 56 (67.47%) 27 (32.53%)   
Vascular tumor    9.806 0.002
 none 76 (38.38%) 122 (61.62%)   
 Micro-Macro 58 (57.43%) 43 (42.57%)   
Race    0.003 0.96
 white 86 (50.89%) 83 (49.11%)   
 asian-blank&Indian 83 (50.61%) 81 (49.39%)